Lanean...
Repigmentation in vitiligo using the janus kinase inhibitor, tofacitinib, may require concomitant light exposure
BACKGROUND: Vitiligo is an autoimmune disease wherein cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors. OBJECTIVE: To evaluate the efficacy of the JAK 1/3 inhibitor, tofacitinib, in the treatment of vitili...
Gorde:
| Argitaratua izan da: | J Am Acad Dermatol |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6233876/ https://ncbi.nlm.nih.gov/pubmed/28823882 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaad.2017.05.043 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|